President Donald Trump has repeatedly promoted his agreements with major pharmaceutical companies as evidence that his administration is finally forcing the industry to lower prescription drug prices for Americans.

But newly disclosed documents reveal that some of those agreements came with significant concessions to the pharmaceutical industry — including protection from Trump’s own tariffs, efforts intended to push drug prices higher overseas, and sweeping confidentiality provisions that kept important details away from the public.

The documents provide a much more complicated picture of agreements that Trump has frequently presented as straightforward victories for American consumers.

The Deals Were More Complicated Than the Announcements

The records detail negotiations between the Trump administration and pharmaceutical giants Pfizer and Eli Lilly.

Both companies agreed to voluntarily reduce prices on certain drugs as part of Trump's "Most Favored Nation" initiative, which seeks to bring some American prescription drug prices closer to those paid in other developed countries.

Trump publicly celebrated the agreements alongside pharmaceutical executives.

Behind the scenes, however, the government was making commitments of its own.

According to the newly released documents, the agreements included protections from pharmaceutical tariffs and provisions involving efforts to encourage higher drug prices in foreign countries.

That second component is particularly important to understanding Trump's strategy.

The administration argues that Americans have effectively subsidized pharmaceutical research and development while other wealthy countries negotiate much lower prices for the same medications.

Trump's solution has been to pressure drug companies to lower prices in the United States while simultaneously pushing other countries to shoulder more of the industry's costs.

In one example cited by the White House, an agreement with the United Kingdom was expected to increase the net price of new prescription drugs there by 25 percent.

Drug Companies Received Protection From Trump's Tariffs

The agreements also intersect with another major Trump policy: tariffs.

Earlier this year, Trump imposed a 100 percent tariff on certain imported patented pharmaceutical products and ingredients.

But pharmaceutical companies were given a way out.

Companies entering qualifying Most Favored Nation pricing agreements and reaching agreements involving American manufacturing could receive a zero-percent tariff through January 20, 2029.

That means some of the same companies publicly agreeing to reduce certain American drug prices were simultaneously receiving protection from potentially enormous import taxes.

The administration argues that this provides companies with an incentive both to lower prices and increase pharmaceutical manufacturing inside the United States.

But the newly disclosed documents show that these arrangements were considerably more complicated than the simple message presented at White House announcements.

The Government Promised Confidentiality

Perhaps one of the most striking revelations involves secrecy.

The Pfizer agreement contained broad confidentiality provisions concerning information associated with the deal.

According to the documents, the Department of Health and Human Services pledged to treat confidential information as exempt from disclosure under the Freedom of Information Act and restrict access to government employees necessary to administer the agreement.

The documents became public only after litigation seeking their release.

Even now, substantial portions remain redacted.

Among the missing information are important financial details and negotiated prices for individual drugs.

That makes independently determining exactly how valuable the agreements are to taxpayers and patients difficult.

Some Details Apparently Weren't Finished When Trump Announced the Deals

The records also reveal another unusual aspect of the agreements.

Some important terms apparently remained unresolved when pharmaceutical executives joined Trump to publicly promote the deals.

That raises questions about exactly what had been finalized when the administration presented the agreements to Americans.

Trump has made prescription drug prices a centerpiece of his domestic agenda and has repeatedly cited the pharmaceutical agreements as one of his administration's major accomplishments.

The White House says its Most Favored Nation agreements now cover 26 pharmaceutical manufacturers representing roughly 89 percent of the branded prescription-drug market.

It also says patients have saved hundreds of millions of dollars through TrumpRx, the administration's prescription-drug discount program.

Those are substantial claims.

But because critical portions of the individual agreements remain secret or redacted, outsiders still have limited ability to independently evaluate their total financial impact.

The White House Says Its Strategy Is Working

The administration maintains that its strategy is delivering exactly what Trump promised.

Its argument is relatively simple: Americans have historically paid disproportionately high prices for prescription medications while wealthy foreign countries negotiate substantially lower prices.

Trump's administration wants pharmaceutical manufacturers to offer Americans comparable prices.

At the same time, it wants other countries to pay more of the cost associated with developing new medications.

The administration has also used the threat of tariffs as leverage, while offering exemptions to pharmaceutical companies willing to participate in its pricing and domestic-manufacturing initiatives.

From the administration's perspective, those concessions aren't giveaways. They are negotiating tools being exchanged for lower American prices and increased investment in American pharmaceutical manufacturing.

Watchdogs Question Who Really Benefits

Consumer advocates examining the newly released documents are considerably more skeptical.

Public Citizen, whose litigation helped obtain the records, argues that too much information remains hidden to determine whether Americans received a favorable deal.

That is ultimately the biggest unanswered question.

Lower prescription drug prices would unquestionably benefit millions of Americans.

But announcing that prices have been lowered is different from providing enough information for the public to independently determine what pharmaceutical companies received in return.

The newly disclosed agreements show that Trump's pharmaceutical initiative wasn't simply a case of the president ordering drug companies to lower their prices and the companies agreeing.

It was a negotiation.

Drug companies offered pricing concessions.

The Trump administration offered concessions of its own.

Some companies received protection from tariffs. The administration pursued higher pharmaceutical prices overseas. Confidentiality provisions shielded portions of the agreements from public scrutiny.

And some of the most important financial details remain unavailable.

Trump has repeatedly portrayed these agreements as evidence of his ability to negotiate with powerful corporations on behalf of Americans.

Now that portions of the actual agreements are finally becoming public, Americans are beginning to see what those negotiations really involved.

And there is still a great deal they haven't been allowed to see.